2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Elderly
PAPER

418 Timing and resolution of oral side effects of talquetamab (Tal) with or without prophylactic interventions in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TALisman

Rahul Banerjee, MD, Vania Hungria, MD, PhD2, Abel Costa, MD3, Niels van de Donk, MD, PhD4, Leo Rasche Jr, MD5, Edvan de Queiroz Crusoé, MD, PhD, MSc6, Carlos Fernandez de Larrea, MD, PhD7, Maria Del Carmen Martinez Chamorro, MD, PhD8, Beth Faiman, PhD, MSN, APN-BC, AOCN®, TCTCN®, FAAN, FAPO9, Junichiro Yuda, MD, PhD10, Kihyun Kim, MD, PhD11, Alexa Laheij12, Richard L. Doty13, James Omel14, Brea Lipe, MD15, Larysa Sanchez, MD16, Ajai Chari, MD17, Alexander Lin18, Hervé Y. Sroussi, DMD, PhD19, Maria Atta20, Jane Robertson, MD21, Mariana Fernandez, MD22, Katy Gray, PhD23, Svetlana Gavrilov24, Kasey Bolyard, MS25, Boo Messahel, MB chB, MD26, Jennifer Schultz27, Keqin Qi28, Diana Cortes-Selva29, Jacqueline Fabry30, Sheri Skerget31, Jenny Zhang32, Kelly Kato, PhD33, Christoph Heuck34, Mark Wildgust, PhD35, Lori Parisi36, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD37
1 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, United States
2 Clinica Médica São Germano, Sao Paulo, Brazil
3 D’or Institute for Research and Education, Sao Paulo, Brazil
4 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
5 University Hospital of Würzburg, Würzburg, Germany
6 Hospital Sao Rafael- Rede D’Or oncologia and Federal University of Bahia, Bahia, Brazil
7 Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer; University of Barcelona, Barcelona, Spain
8 Hospital Universitario Quirónsalud Pozuelo; Universidad Europea de Madrid, Madrid, Spain
9 Cleveland Clinic, Cleveland, United States
10 National Cancer Center Hospital East, Kashiwa, Japan
11 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Rep. of South
12 Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, and Amsterdam UMC Medical Centers, University of Amsterdam, Amsterdam, Netherlands
13 University of Pennsylvania, Philadelphia, United States
14 The Central Nebraska Myeloma Support Group, Grand Island, United States
15 University of Rochester Medical Center, Rochester, United States
16 Icahn School of Medicine at Mount Sinai, New York, United States
17 University of California, San Francisco, San Francisco, United States
18 University of Pennsylvania, Philadelphia, United States
19 Brigham and Women’s Hospital, and Harvard School of Dental Medicine, Boston, United States
20 Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
21 The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
22 Johnson & Johnson, Madrid, Spain
23 Johnson & Johnson, Bridgewater, United States
24 Johnson & Johnson, Raritan, United States
25 Johnson & Johnson, Raritan, United States
26 Johnson & Johnson, Raritan, United States
27 Johnson & Johnson, Titusville, United States
28 Johnson & Johnson, Titusville, United States
29 Johnson & Johnson, Spring House, United States
30 Johnson & Johnson, Spring House, United States
31 Johnson & Johnson, Spring House, United States
32 Johnson & Johnson, Spring House, United States
33 Johnson & Johnson, Raritan, United States
34 Johnson & Johnson, Spring House, United States
35 Johnson & Johnson, Raritan, United States
36 Johnson & Johnson, Raritan, United States
37 University College London Hospitals NHS Foundation Trust, London, London, United Kingdom

Introduction: Tal has demonstrated durable responses in RRMM; however, pts treated with Tal often experience taste changes (eg, dysgeusia) and oral adverse events (AEs). Understanding the clinical course of oral AEs and expectations for resolution with and without prophylaxis may encourage pts to remain on Tal to achieve maximum clinical benefits. The TALisman study has shown that dysgeusia with Tal begins to improve after 3–4 months using longitudinal objective assessment with the Waterless Empirical Taste Test (WETT). Mitigation of Tal-related oral AEs with prophylactic therapy has potential to improve outcomes; however, some therapies may compound AEs, including taste changes, as up to 50% of commonly prescribed therapies generate chemosensory complaints. We present follow-up with additional WETT and conventional subjective assessments to further characterize the clinical course of dysgeusia, xerostomia, dysphagia, and mucositis with or without dexamethasone (dex) mouthwash, pregabalin (pgb) capsules, or clonazepam (czp) oral disintegrating tablets as prophylaxis, and potentially demonstrate that agents often used to manage oral AEs may bring additive taste changes and delay improvements.

Methods: In the ongoing, phase 2 TALisman (NCT06500884) study, pts with RRMM are randomized to receive experimental prophylaxes for 7 days before the first Tal step-up dose or no prophylactic intervention (Tal only). Primary endpoints are incidence of dysgeusia and severe dysgeusia, time to onset of severe dysgeusia, and rate of resolution/improvement of dysgeusia, at the end of Months 3 and 7 per WETT. WETT uses taste strips to evaluate 5 taste components (Sweet, Salty, Sour, Bitter, and Umami [Brothy]), each scored 0 to 8, and “no taste” strips scored 0 to 13. Secondary endpoints include assessment of oral AEs per Common Terminology Criteria for Adverse Events (CTCAEs) and their impact on health-related quality of life.

Results: As of April 2026, 68% of pts with Tal only (n=25), 60% with Tal+dex (n=15), 75% with Tal+pgb (n=16), and 64% with Tal+czp (n=14) had ≥6 cycles of Tal. By WETT, dysgeusia rates were higher with all prophylaxes vs Tal only, with severe dysgeusia occurring in 56% of Tal only pts and 86%, 87%, and 100% of pts receiving czp, dex, and pgb prophylaxis, respectively. Across cohorts the onset of dysgeusia was detected earlier with WETT (Tal only and Tal+dex, 8 days (d); Tal+pgb,10 d; Tal+clon, 4 d) than with CTCAE (Tal only, 15 d; Tal+dex, 10 d; Tal+pgb, 16 d; Tal+clon, 11 d). Most pts (57–59%) in the Tal only, pgb, and czp cohorts had improvement/resolution of dysgeusia, per WETT, by the end of Month 3, vs 33% of pts with dex. By the end of Month 7, dysgeusia had improved/resolved in 4/7 evaluable pts (57%) with Tal only. The declines in mean WETT component scores (Sweet, Salty, Sour, Bitter, Brothy) were generally greater for the prophylaxis cohorts than Tal only. The greatest mean WETT changes from baseline at C3D15 were in Sweet and Salty taste, particularly with Tal+dex (−4.92 and −4.08, respectively, vs −2.55 and −2.36, respectively, with Tal only). Dysgeusia and xerostomia (per CTCAE) were most common in the prophylaxis cohorts (dysgeusia: 60% [Tal only] vs 73% [Tal+dex], 81% [Tal+pgb], and 93% [Tal+czp]; xerostomia: 32% [Tal only] vs 47% [Tal+dex], 75% [Tal+pgb], and 64% [Tal+czp]). Rates of dysphagia and oral mucositis were highest in the Tal+dex cohort (dysphagia: 40% for Tal+dex vs 25−32% for other cohorts; oral mucositis: 33% for Tal+dex vs 7−13% for other cohorts). Mild decreases in mean weight as a percentage of baseline were observed across cohorts. Longer follow-up data, including timing and resolution of oral AEs, detailed WETT trajectories, patient-reported treatment-related symptoms, and saliva profiling will be presented at the meeting.

Conclusions: TALisman provides a comprehensive prospective characterization of Tal-related oral AEs, showing that WETT supports earlier detection and monitoring of dysgeusia, which improved or resolved in most patients after 3 months. Importantly, the study demonstrated limited utility of select prophylactic approaches, particularly dex mouthwash, which can be associated with the development of oral thrush. These findings provide immediately actionable, practice-informing guidance for healthcare providers, provide information to better educate pts, set expectations regarding symptom timing and recovery, and optimize supportive care during treatment.
Rahul Banerjee, MD: BMS - Research Funding; Sanofi - Research Funding; Abbvie - Research Funding; Prothena - Research Funding; Johnson & Johnson - Research Funding; Pack Health - Research Funding; Novartis - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); SparkCures - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Poseida Therapeutics - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Adaptive Biotech - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Gilead/Kite - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony)